Scheduled start 15.06.2021.

AIMPID is focused on predicting mutations in SARS-CoV-2 genome and developing small inhibitor molecules  which target the virulent protein products of predicted mutations to block their activities. This helps in controlling the spread of pandemic as frequent mutations in SARS-CoV-2 genome (especially in case of targeted rna vaccines) are taking place rendering the developed drugs useless. Being an RNA virus, SARS-CoV-2 is prone to mutations therefore, it necessitates the tracing of mutation patterns in the viral genome to find the least mutable regions in order to design enduring and more stable inhibitor molecules. The main tasks constituting the conduction of the whole project are mutation rate prediction, mutation prediction and development of small inhibitor molecules against proteins translated from mutated RNA sequences.